BridgeBio Oncology Therapeutics, Inc. — Third Quarter 2026 Earnings Summary

BridgeBio Oncology Therapeutics reported third-quarter 2026 financial results showing a net loss of $34.2 million and cash reserves of $315.3 million sufficient to fund operations into 2029. The company's lead candidate BBO-8520 demonstrated a 75% objective response rate when combined with pembrolizumab in KRASG12C inhibitor-experienced non-small cell lung cancer patients. Clinical development continues for BBO-11818 and BBO-10203 combination therapies in colorectal and pancreatic cancers, with monotherapy data updates expected in the fourth quarter of 2026. Research and development expenses decreased to $29.6 million from $35.1 million in the prior year period, while general and administrative expenses fell to $7.9 million.